Document is current
Any future updates will be listed below
-
Authors
Kittipibul, Veraprapas
Lam, Carolyn S. P.
- License Information
-
More Information
Article History
Accepted: 13 January 2025
First Online: 24 January 2025
Declarations
:
: Dr. Kittipibul has no disclosures. Dr. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from NovoNordisk and Roche Diagnostics; has served as consultant or on the Advisory Board, Steering Committee, or Executive Committee for Alleviant Medical, Allysta Pharma, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Quidel Corporation, Radcliffe Group, Recardio, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; serves as Cofounder and Non-executive Director of Us2.ai; and has the following patents issued or pending: PCT/SG2016/050217 (for a method for diagnosis and prognosis of chronic heart failure) and US Patent number 10702247 (for an automated clinical workflow that recognizes and analyzes two-dimensional and Doppler echo images for cardiac measurements and the diagnosis, prediction, and prognosis of heart disease).
